We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 05, 2021

Bleeding Risk With Rivaroxaban vs Vitamin K Antagonists in Elderly Patients With Atrial Fibrillation

Heart (British Cardiac Society)

 

Additional Info

Heart (British Cardiac Society)
Bleeding Risk With Rivaroxaban Compared With Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation
Heart 2020 Dec 01;[EPub Ahead of Print], O Hanon, JS Vidal, G Pisica-Donose, G Orvoën, JP David, E Chaussade, L Caillard, LW de Jong, N Boulloche, U Vinsonneau, S Bouée, P Krolak-Salmon, L Fauchier, P Jouanny, G Sacco, F Bellarbre, J Belmin, F Puisieux, M Lilamand, E Paillaud, AS Boureau

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading